(Q42264312)

English

Incidence of hepatotoxic side effects during antituberculous therapy (INH, RMP, EMB) in relation to the acetylator phenotype (author's transl)

scientific article published on May 1982

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

19 October 2017

Incidence of hepatotoxic side effects during antituberculous therapy (INH, RMP, EMB) in relation to the acetylator phenotype (author's transl) (English)

1 reference

Europe PubMed Central

19 October 2017

1 reference

based on heuristic

inferred from title

author name string

E Musch

1

1 reference

Europe PubMed Central

19 October 2017

M Eichelbaum

2

1 reference

Europe PubMed Central

19 October 2017

J K Wang

3

1 reference

Europe PubMed Central

19 October 2017

W von Sassen

4

1 reference

Europe PubMed Central

19 October 2017

M Castro-Parra

5

1 reference

Europe PubMed Central

19 October 2017

H J Dengler

6

1 reference

Europe PubMed Central

19 October 2017

language of work or name

0 references

publication date

1 May 1982

1 reference

Europe PubMed Central

19 October 2017

Klinische Wochenschrift

1 reference

Europe PubMed Central

19 October 2017

60

1 reference

Europe PubMed Central

19 October 2017

10

1 reference

Europe PubMed Central

19 October 2017

513-519

1 reference

Europe PubMed Central

19 October 2017

Isoniazid liver injury: clinical spectrum, pathology, and probable pathogenesis

1 reference

https://api.crossref.org/works/10.1007%2FBF01756097

21 January 2018

[Detection of the effects of the rifampin-isoniazid combination on the human liver]

1 reference

https://pubmed.ncbi.nlm.nih.gov/7098379

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The IUAT trial on isoniazid preventive treatment in persons with fibrotic lung lesions

1 reference

https://pubmed.ncbi.nlm.nih.gov/7098379

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Kinetic studies on rifampicin. I. Serum concentration analysis in subjects treated with different oral doses over a period of two weeks

1 reference

https://pubmed.ncbi.nlm.nih.gov/7098379

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Pharmacokinetics of isoniazid metabolism in man

1 reference

https://pubmed.ncbi.nlm.nih.gov/7098379

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Adverse reactions to short-course regimens containing streptomycin, isoniazid, pyrazinamide and rifampicin in Hong Kong

1 reference

https://pubmed.ncbi.nlm.nih.gov/7098379

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

[The liver and rifampicin].

1 reference

https://pubmed.ncbi.nlm.nih.gov/7098379

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Rifampin plus isoniazid in initial therapy of pulmonary tuberculosis and rifampin and ethambutol in retreatment cases

1 reference

https://pubmed.ncbi.nlm.nih.gov/7098379

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Hepatic dysfunction in tuberculous patients treated with rifampicin and isoniazid

1 reference

https://pubmed.ncbi.nlm.nih.gov/7098379

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Sulphadimidine Acetylation Test for Classification of Patients as Slow or Rapid Inactivators of Isoniazid

1 reference

https://pubmed.ncbi.nlm.nih.gov/7098379

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

[Maximal induction onset and induction time of drug catabolizing human enzymes after administration of rifampicin]

1 reference

https://pubmed.ncbi.nlm.nih.gov/7098379

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Hepatitis cases in isoniazid treated groups and in a control group

1 reference

https://pubmed.ncbi.nlm.nih.gov/7098379

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

[Jaundice and rifampicin. Critical study]

1 reference

https://pubmed.ncbi.nlm.nih.gov/7098379

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Toxicity form rifampicin plus isoniazid and rifampicin plus ethambutol therapy

1 reference

https://pubmed.ncbi.nlm.nih.gov/7098379

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Rifampicin hepatitis. A clinical and histological study

1 reference

https://pubmed.ncbi.nlm.nih.gov/7098379

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Rifomycin in the treatment of pulmonary tuberculosis: preliminary note

1 reference

https://pubmed.ncbi.nlm.nih.gov/7098379

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Increased incidence of isoniazid hepatitis in rapid acetylators: possible relation to hydrazine metabolites

1 reference

https://pubmed.ncbi.nlm.nih.gov/7098379

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Co-operative controlled trial of a standard regimen of streptomycin, PAS and isoniazid and three alternative regimens of chemotherapy in Britain. A report from the British Medical Research Council

1 reference

https://pubmed.ncbi.nlm.nih.gov/7098379

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Hepatotoxic side-effects of rifampicin; a comparative clinical study (author's transl)

1 reference

https://pubmed.ncbi.nlm.nih.gov/7098379

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Isoniazid-associated hepatitis in 114 patients

1 reference

https://pubmed.ncbi.nlm.nih.gov/7098379

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

HUMAN ACETYLATION POLYMORPHISM

1 reference

https://pubmed.ncbi.nlm.nih.gov/7098379

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Adverse reactions to rifampicin in antituberculosis regimens

1 reference

https://pubmed.ncbi.nlm.nih.gov/7098379

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

[Clinical trial of rifampicin as sole therapy. Study of serum levels]

1 reference

https://pubmed.ncbi.nlm.nih.gov/7098379

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Hepatoxic side-effects of rifampicin. A comparative clinical study

1 reference

https://pubmed.ncbi.nlm.nih.gov/7098379

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1007/BF01756097

1 reference

Europe PubMed Central

19 October 2017

1 reference

Europe PubMed Central

19 October 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q42264312&oldid=1940692687"